In a patient with controlled blood pressure on benazepril 10 mg daily, hydrochlorothiazide 25 mg daily, and potassium chloride 60 mEq daily, with serum potassium at the low‑normal limit (3.5 mmol/L), should any medications be changed?

Medication Management Recommendation

I would discontinue the potassium chloride supplement and consider switching from hydrochlorothiazide to a thiazide-like diuretic (chlorthalidone or indapamide) or adding a potassium-sparing agent like spironolactone instead of continuing potassium supplementation.

Rationale for Discontinuing Potassium Supplementation

Your patient's serum potassium of 3.5 mmol/L is at the lower limit of normal but not truly hypokalemic. The FDA label for benazepril explicitly warns that ACE inhibitors can cause hyperkalemia, and concurrent use with potassium supplements increases this risk 1. The guideline states that "serum potassium should be monitored periodically in patients receiving benazepril" and identifies "concomitant use of potassium supplements" as a specific risk factor for hyperkalemia 1.

Key consideration: While the patient currently has low-normal potassium, the ACE inhibitor (benazepril) has potassium-retaining effects that counteract the potassium-wasting effects of HCTZ. Continuing 60 mEq of potassium supplementation creates unnecessary risk for future hyperkalemia, especially if renal function declines or dietary potassium intake increases.

Optimizing the Diuretic Regimen

The 2025 AHA/ACC guideline recommends that when optimizing resistant hypertension treatment, "replacing thiazide-type diuretics (eg, HCTZ or bendroflumethiazide) with thiazide-like diuretics (eg, chlorthalidone and indapamide) may offer additional BP reduction and cardiovascular protection" 2. The 2024 ESC guidelines similarly recommend "thiazides and thiazide-like drugs such as chlorthalidone and indapamide" as first-line agents 3.

Evidence shows:

• Chlorthalidone at 12.5-75 mg reduces blood pressure by 12/4 mmHg compared to placebo 4
• Hydrochlorothiazide 25 mg reduces blood pressure by 8/3 mmHg 4
• Both cause similar potassium depletion at equivalent doses 5

Since blood pressure is already controlled, switching to chlorthalidone isn't necessary for BP control but could provide superior cardiovascular protection.

Alternative Strategy: Potassium-Sparing Diuretic

If you prefer to maintain HCTZ, consider adding low-dose spironolactone (12.5-25 mg) while discontinuing both HCTZ and potassium supplementation, then restarting HCTZ if needed. The 2025 guideline notes that spironolactone 25-50 mg as a fourth agent reduced BP by 6.6-8.7 mmHg in resistant hypertension 2. However, 4-40% of patients cannot tolerate spironolactone due to hyperkalemia or antiandrogenic effects 2.

Practical approach:

• Spironolactone 12.5-25 mg would eliminate the need for potassium supplementation
• Monitor potassium closely (risk of hyperkalemia with ACE inhibitor combination) 1
• Research shows that among hydrochlorothiazide users, fixed-dose combination therapy had the lowest risk of hypokalemia (adjusted OR 0.32) compared to monotherapy 6

Monitoring Plan

After discontinuing potassium supplementation:

• Recheck serum potassium in 1-2 weeks, then monthly for 3 months
• The FDA label emphasizes that "serum potassium should be monitored periodically" with benazepril 1
• Target potassium range: 3.5-5.0 mmol/L
• If potassium drops below 3.0 mmol/L, consider adding a potassium-sparing diuretic rather than restarting supplementation

Common Pitfalls to Avoid

Do not routinely supplement potassium in patients on ACE inhibitors: Research from 1993 states "routine prophylactic use of potassium-sparing diuretics in combination with non-potassium-retaining diuretics for the treatment of hypertension...is not justified" 7. This applies even more when an ACE inhibitor is present.

Recognize that 60 mEq is a substantial dose: Among hydrochlorothiazide users taking potassium supplements, 27.2% on monotherapy still had hypokalemia 6, suggesting that supplementation is often inadequate or excessive depending on individual factors.

Monitor for hyperkalemia risk factors: The benazepril label lists "renal insufficiency, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements" as specific risk factors 1. Your patient has at least one of these risks currently.